Laurent Rigal, Constance Alexandre-Dubroeucq, Renaud de Beaurepaire2, Claire Le Jeunne and Philippe Jaury – Alcohol and Alcoholism Advance Access published March 19, 2012
Abstract — Aims: The aim of the study was to assess the proportions of ‘high-risk’ drinkers’ abstinent or with ‘low-risk’ consumption
levels 1 year after the initiation of high-dose baclofen. Methods: This is a retrospective ‘open’ study; the outcome of this study
was to assess the level of alcohol consumption in the 12th month of treatment. Results: Of the 181 patients included, a follow-up
evaluation was possible in 132 patients. The initial alcohol consumption of the 132 patients analysed averaged 182 ± 92 g/day. After
1 year, 80% of the 132 (i.e. 58% of 181) were either abstinent (n = 78) or drinking at low-risk levels (n = 28) in their 12th month of
treatment. The mean baclofen dose at 1 year was 129 ± 71 mg/day. Conclusion: High-dose baclofen should be tested in randomized
placebo-controlled trials among high-risk drinkers.